



ERG\NEO

L'AVENIR EST FAIT D'AUDACE



Paris, 06/24/2025

Press release

The new artificial intelligence-based stroke prediction device

Start-up Octogone Medical and Erganeo sign exclusive license for non-invasive stroke risk prediction system. A joint innovation by Octogone Medical, Université Paris Cité, INSERM and AP-HP.

Cerebrovascular accident (CVA) is a disease on the rise throughout the world: it is the third leading cause of death and the leading source of non-traumatic motor disability. Carotid plaque rupture has been shown to play a major role in 70% of ischemic strokes - caused by occlusion of an artery in the brain.

With this in mind, the research team led by Prof. Emmanuel Messas (Université Paris Cité, AP-HP - Assistance publique-Hôpitaux de Paris) and Dr. Frédéric Saldmann has developed a new system for predicting plaque rupture.

The system, designed for people at risk, is based on a medical monitoring device. It is offered in the form of an external patch, equipped with sensors that continuously measure the state of vascular plaques (risk of rupture or vascular plaque detachment) and/or the biomechanical properties of the carotid wall. The data collected is analyzed by artificial intelligence, to predict the risk of stroke non-invasively and in real time.

This momentum was continued with the creation, in October 2020, of start-up Octogone Medical, co-founded by Emmanuel Messas and Frédéric Saldmann. Three families of patents¹ were subsequently filed between 2021 and 2023, then extended internationally to Europe, China and the United States.

Erganeo's contribution to valorizing this invention took the form of legal support and an exclusive licensing agreement, signed on April 25, 2025. "Octogone is a promising start-up that will enable the international dissemination of a technology developed by French public research, with a strong medical impact," explains Naceur Tounekti, President of Erganeo.

This collaboration will enable the start-up to launch the entry into clinical phases in France and Europe in 2025, followed by the marketing phase planned for 2027 in Europe.

¹ CNRS (Centre National de la Recherche Scientifique), INSERM (Institut National de la Santé et de la Recherche Médicale), AP-HP (Assistance publique-Hôpitaux de Paris), Université Paris Cité and Octogone Medical



ERG\NEO

L'AVENIR EST FAIT D'AUDACE



About Erganeo – www.erganeo.com

Erganeo is a French technology transfer company specializing in disruptive innovations (DeepTech) with high societal impact. We invest at the earliest stage to secure researchers' new inventions, before they are transferred to industry or start-ups are created, in a wide range of scientific fields: Biotech (health, agrifood, environment, cosmetics), Infotech (telecoms, Internet of Things, big data, AI), Eneritech (green energies, chemistry, materials) and more. Our mission is to accelerate and simplify associations between Research and Industry, in favor of societal progress. To achieve this, we finance and support the new generation of French researcher-entrepreneurs, helping them to achieve success and international recognition.

As a member of the SATT network, Erganeo draws the foundations of a desirable future from the Paris region ecosystem, a rich breeding ground for innovation with 20,000 researchers in over 350 cutting-edge research laboratories. Since its creation, Erganeo has invested over €44.4 million, helping to sign 130 licenses with companies of all sizes and create 37 start-ups.

Press contact : Caroline Pontifice - Communications and Marketing Manager - caroline.pontifice@erganeo.com

About Octogone Medical – www.octogone-medical.com

Founded on October 15, 2020, Octogone Medical is a start-up specializing in the analysis of scientific and medical innovations on an international scale. It develops intelligent databases, assesses therapeutic risks and identifies the most advanced prevention solutions. The company is involved in both the creation of medical devices and pharmaceutical research. Its approach combines health, well-being, nutrition and cutting-edge technologies.

Press contact : Antonin Saldmann - CTO - a.saldmann@octogone-medical.com